Cargando…
Anti-PD-1 Therapy-Associated Perforating Colitis
Inhibition of immune checkpoint T cell regulatory molecules by using programmed cell death protein 1 (PD-1), or its ligand (PDL-1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has been increasingly used to treat advanced malignancies. The immune-related adverse effects associated with t...
Autores principales: | Celli, Romulo, Kluger, Harriet M., Zhang, Xuchen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000840/ https://www.ncbi.nlm.nih.gov/pubmed/29955400 http://dx.doi.org/10.1155/2018/3406437 |
Ejemplares similares
-
Pathology of Alcoholic Liver Disease
por: Celli, Romulo, et al.
Publicado: (2014) -
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report
por: d’Apolito, Maria, et al.
Publicado: (2022) -
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015) -
A case of spontaneous colonic perforation in collagenous colitis
por: Mori, Haruki, et al.
Publicado: (2019) -
B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors
por: Damsky, William, et al.
Publicado: (2019)